Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial Meeting Abstract
| Authors: | Janjigian, Y.; Rha, S.; Oh, D.; Díez García, M.; van Laarhoven, H.; Chao, Y.; Di Bartolomeo, M.; Haj Mohammad, N.; Zhong, W.; Croydon, E.; Cecchi, F.; Lee, J. |
| Abstract Title: | Co-occurring HER2 and PD-L1 expression in patients with HER2-positive trastuzumab-refractory gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Biomarker analysis from the trastuzumab deruxtecan (T-DXd) DESTINY-Gastric03 trial |
| Meeting Title: | ESMO 24th World Congress on Gastrointestinal Cancer 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2022 Jun 29-Jul 2 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-06-01 |
| Start Page: | S358 |
| End Page: | S359 |
| Language: | English |
| ACCESSION: | WOS:000823826500327 |
| DOI: | 10.1016/j.annonc.2022.04.406 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: SO-7 -- Source: Wos |
